Working with TipRanks
Follow Us
Research Tools
Calendars
Calculators
Education
About Us
Working with TipRanks
Follow Us
Fate Therapeutics (FATE)
NASDAQ:FATE
Fate Therapeutics (FATE) Stock Price & Analysis
1,027 Followers
FATE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.99 - $23.96
Previous Close$2.18
Volume305.68K
Average Volume (3M)2.28M
Market Cap
$212.40M
Enterprise ValueN/A
Total Cash (Recent Filing)$377.94M
Total Debt (Recent Filing)$106.35M
Price to Earnings (P/E)-1.0
Beta2.07
Next Earnings
Nov 02, 2023EPS Estimate
-$0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.17
Shares Outstanding98,562,432
10 Day Avg. Volume4,300,911
30 Day Avg. Volume2,283,333
Standard Deviation0.19
R-Squared0.17
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)0.45
Price to Sales (P/S)221.84
Price to Cash Flow (P/CF)-1.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$6.71Price Target Upside211.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Fate Therapeutics News
Pre-EarningsFATE Upcoming Earnings Report: What to Expect?
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Product Insights
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
FATE FAQ
What was Fate Therapeutics’s price range in the past 12 months?
Fate Therapeutics lowest stock price was $1.99 and its highest was $23.96 in the past 12 months.
What is Fate Therapeutics’s market cap?
Currently, no data Available
When is Fate Therapeutics’s upcoming earnings report date?
Fate Therapeutics’s upcoming earnings report date is Nov 02, 2023 which is in 34 days.
How were Fate Therapeutics’s earnings last quarter?
Fate Therapeutics released its earnings results on Aug 08, 2023. The company reported -$0.54 earnings per share for the quarter, beating the consensus estimate of -$0.589 by $0.049.
Is Fate Therapeutics overvalued?
According to Wall Street analysts Fate Therapeutics’s price is currently Undervalued.
Does Fate Therapeutics pay dividends?
Fate Therapeutics does not currently pay dividends.
What is Fate Therapeutics’s EPS estimate?
Fate Therapeutics’s EPS estimate is -$0.56.
How many shares outstanding does Fate Therapeutics have?
Fate Therapeutics has 98,562,430 shares outstanding.
What happened to Fate Therapeutics’s price movement after its last earnings report?
Fate Therapeutics reported an EPS of -$0.54 in its last earnings report, beating expectations of -$0.589. Following the earnings report the stock price went down -3.683%.
Which hedge fund is a major shareholder of Fate Therapeutics?
Among the largest hedge funds holding Fate Therapeutics’s share is Baker Bros Advisors LP. It holds Fate Therapeutics’s shares valued at 8M.
---
Fate Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.71 (211.37% Upside)
$6.71 (211.37% Upside)
Blogger Sentiment
Bullish
FATE Sentiment 100%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Increased
By 98.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $32.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 6.9%
Last 30 Days ▼ 6.9%
News Sentiment
Neutral
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-90.56%
12-Months-Change
Fundamentals
Return on Equity
-41.55%
Trailing 12-Months
Asset Growth
-27.54%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Fate Therapeutics
Fate Therapeutics, Inc. operates as a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder. The firm programme cellular therapeutics for the treatment of life threatening diseases, hematologic malignancies, genetic disorders and diseases resulting from the dysregulation of the immune system. Its products include ProHema, ProTmune, Adaptive NK, iPSC-derived NK, Programmed CD34 and T cell therapy. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.
---
Top 5 ETFs holding FATE
Vanguard Total Stock Market ETF
$6.43M
Vanguard Health Care ETF
$676.25K
Fidelity Nasdaq Composite Index ETF
$123.05K
iShares Russell 3000 ETF
$43.70K
Vanguard Russell 3000 ETF
$14.43K
Up to five ETFs with an Outperform Smart Score that hold FATE. The ETFs are listed according to market value of FATE within the ETF
---